Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability

Clinical Therapeutics

Volumn 24, Issue 11, 2002, Pages 1915-1936

  Lode, Hartmut ^a   File Jr , Thomas M ^b   Mandell, Lionel ^c   Ball, Peter ^d   Pypstra, Rienk ^e   Thomas, Michael ^e  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b SUMMA HEALTH SYSTEM   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Ceftriaxone; Cefuroxime; Community acquired pneumonia; Gemifloxacin; Hospitalized patients; Oral therapy

Indexed keywords

CEFTRIAXONE; CEFUROXIME; GEMIFLOXACIN; LIVER ENZYME; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CANDIDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFECTION RISK; LEGIONELLA PNEUMOPHILA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; OPEN STUDY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; STREPTOCOCCUS PNEUMONIAE;

EID: 0036861678     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80088-1     Document Type: Article

References (46)

1. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347-382.
2. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A metaanalysis. JAMA. 1996;275:134-141.
3. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalizations: Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997;157:1709-1718.
4. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
5. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449-2454.
6. Siegel R. How short can courses be in lower respiratory tract infections? J Int Med Res. 2000;28(Suppl 1):37A-47A.
7. Vogel F. Sequential therapy in the hospital management of lower respiratory infections. Am J Med. 1995;99:14S-19S.
8. Collignon PJ. Intravascular catheter associated sepsis: A common problem. The Australian Study on intravascular catheter associated sepsis. Med J Aust. 1994;161: 374-378.
9. Morrissey I, George JT. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J Antimicrob Chemother. 2000;45(Suppl 1):101-106.
10. Hoban DJ, Bouchillon SK, Karlowsky JA, et al. A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. Antimicrob Agents Chemother. 2000;44:3008-3011.
11. Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999;341:233-239.
12. McCloskey L, Moore T, Niconovich N, et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J Antimicrob Chemother. 2000;45(Suppl 1):13-21.
13. Roblin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother. 1999;43:2806-2807.
14. Duffy LB, Crabb D, Searcey K, Kempf MC. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother. 2000;45(Suppl 1):29-33.
15. Dubois J, St-Pierre C. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. J Antimicrob Chemother. 2000;45(Suppl 1):41-46.
16. File TM Jr, Schlemmer B, Garau J, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother. 2001;48:67-74.
17. Ball P, File TM Jr, Twynholm M, Henkel T. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents. 2001;18:19-27.
18. Léophonte P, Schlemmer B, Goldstein F, et al. Efficacy and safety of once daily gemifloxacin (GEMI) for the treatment of community-acquired pneumonia (CAP) of suspected pneumococcal origin. In: Abstracts of the 20th Interdisciplinary Meeting on Anti-infectious Chemotherapy; December 7-8, 2000; Paris, France. Abstract 143/P1.
19. Cupo M, Pypstra R, Young C. Safety of gemifloxacin in adult patients with respiratory and urinary tract infections. Paper presented at: 7th Conference of the Federation of Infection Societies; November 29-December 1, 2000; Manchester, United Kingdom. Abstract P28.
20. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic stepdown therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother. 1995;29:561-565.
21. Oh HM, Ng AW, Lee SK. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J. 1996;37:255-257.
22. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4. 4th ed. Wayne, Pa: NCCLS; 1997.
23. Performance Standards for Antimicrobial Disk Susceptibility Tests. Eighth Informational Supplement. Approved Standard M100-S8. Wayne, Pa: NCCLS; 1998.
24. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000;31:383-421.
25. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest. 2001;119:185-195.
26. Moola S, Hagberg L, Churchyard GA, et al. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest. 1999;116:974-983.
27. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxicillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 1997;40(Suppl A):73-81.
28. File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1965-1972.
29. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest. 2001;119:1439-1448.
30. Kalbermatter V, Bagilet D, Diab M, Javkin E. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization [in Spanish]. Med Clin (Barc). 2000;115:561-563.
31. Kahn JB, Wiesinger A, Olson WH, et al. Levofloxacin vs. ceftriaxone and erythromycin in the treatment of patients with community-acquired pneumonia (CAP) at high risk of mortality. J Antimicrob Chemother. 2001;47(Suppl S1):45. Abstract P115.
32. Music E, Tomic V, Erzen R. First experience with moxifloxacin in community acquired hospital treated respiratory tract infections (RTI). J Antimicrob Chemother. 2001;47(Suppl S1):47. Abstract P124.
33. Vogel F, Lode H. The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia. J Antimicrob Chemother. 1991;28(Suppl C):81-86.
34. Sanders WE Jr, Morris JF, Alessi P, et al. Oral ofloxacin for the treatment of acute bacterial pneumonia: Use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am J Med. 1991;91:261-266.
35. Garau J. The hidden impact of antibacte-rial resistance in respiratory tract infection. Clinical failures: The tip of the iceberg? Respir Med. 2001;95(Suppl A):S5-S11.
36. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med. 1991;325:520-521.
37. Davies BI, Maesen FP. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: The relationship with in-vitro activity. J Antimicrob Chemother. 1999;43 (Suppl C):83-90.
38. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
39. c interval prolongation and torsades de pointes. Pharmacotherapy. 2001;21:301-319.
40. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis. 1999;28:352-364.
41. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother. 1996;37(Suppl A):161-167.
42. c prolongation associated with levofloxacin. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Abstract 822.
43. c interval in healthy volunteers. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Abstract 821.
44. Blaser MJ, Klaus BD, Jacobson JA, et al. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia. Antimicrob Agents Chemother. 1983;24:163-167.
45. Laing RB, Mackenzie AR, Shaw H, et al. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards. J Antimicrob Chemother. 1998;42:107-111.
46. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273-1276.